| Biomarker ID | 835 |
| PMID | 22213075 |
| Year | 2011 |
| Biomarker | Mutation Status of HSD17B2 |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Allelic Loss in HSD17B2 in Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | HR = 1.97, (95% CI: 1.06–3.64) |
| Effect on Pathways | Pathways Include:- Steroid biosynthesis,Steroid hormone biosynthesis,Oncostatin M, Metabolism |
| Experiment | Biochemical Recurrenece (5 years) |
| Type of Biomarker | Prognostic |
| Cohort | 126 men with intermediate-risk disease were chosen for the study out of which 47 experiened relapse. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.031 |
| Method Used | Microarray-based Comparative Genomic Hybridization |
| Clinical | No |
| Remarks | The results were validated in a surgical cohort of 131 intermediate-risk patients |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | HSD17B2 |